Biogen (BIIB) Stock Price, News & Analysis

Company Overview

Biogen Inc (NASDAQ:BIIB) is a global biotechnology company focused on the discovery, development and delivery of therapies for the treatment of neurological and neurodegenerative diseases. The company’s core business encompasses research in multiple sclerosis, spinal muscular atrophy, amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. Its portfolio includes several market-leading products such as Tecfidera and Tysabri for multiple sclerosis, Spinraza for spinal muscular atrophy, and Fumaderm for psoriasis. Biogen also actively advances research in next-generation gene therapies and antibody-based treatments, leveraging its expertise in molecular biology, translational medicine and innovative drug delivery platforms.

Founded in 1978 by a group of visionary scientists in Geneva, Switzerland, Biogen established itself early on as a pioneer in recombinant DNA technology. The company maintains its global headquarters in Cambridge, Massachusetts, and operates research and development facilities in the United States, Europe and Asia. Its commercial footprint spans nearly 90 countries, with significant market presence in North America, Europe, Japan and key emerging markets. Over the years, Biogen has pursued strategic collaborations and licensing agreements with academic institutions, biotechnology startups and larger pharmaceutical companies to expand its pipeline and optimize global distribution channels.

Led by Chief Executive Officer Michel Vounatsos, Biogen’s executive team brings together seasoned leaders from the biotechnology and pharmaceutical sectors, underpinned by a strong commitment to research excellence and patient-centric innovation. The company emphasizes disciplined capital allocation, operational efficiency and strategic partnerships to accelerate the development of transformative therapies. Beyond its scientific endeavors, Biogen has established corporate responsibility initiatives focused on access to healthcare, environmental sustainability and community engagement, reflecting its mission to improve the lives of patients around the world.

Key Stats

• Today's Range: $132.21 to $134.42
• 50-Day Range: $116.92 to $135.49
• 52-Week Range: $110.04 to $238.00
• Volume: 633,328 shs
• Average Volume: 1.43 million shs
• Market Capitalization: $19.43 billion
• P/E Ratio: 13.09
• Dividend Yield: N/A
• Price Target: $188.48
• Consensus Rating: Hold

Biogen Stock Analysis - MarketRank™

Biogen scored higher than 99% of companies evaluated by MarketBeat, and ranked 40th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

Biogen has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 12 buy ratings, 20 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Biogen has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 4.30%

Earnings Growth

Earnings for Biogen are expected to grow by 4.30% in the coming year, from $15.83 to $16.51 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Biogen is 13.09, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.53.

Price to Earnings Ratio vs. Sector

The P/E ratio of Biogen is 13.09, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.40.

Price to Earnings Growth Ratio

Biogen has a PEG Ratio of 1.06. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Biogen has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.32% of the float of Biogen has been sold short.

Short Interest Ratio / Days to Cover

Biogen has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biogen has recently decreased by 10.79%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biogen does not currently pay a dividend.

Dividend Growth

Biogen does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.7 / 5
• Environmental Score: -1.95

Percentage of Shares Shorted

2.32% of the float of Biogen has been sold short.

Short Interest Ratio / Days to Cover

Biogen has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biogen has recently decreased by 10.79%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 0.91

News Sentiment

Biogen has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 26 news articles for Biogen this week, compared to 23 articles on an average week.

Search Interest

30 people have searched for BIIB on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.

MarketBeat Follows

12 people have added Biogen to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Biogen insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.18% of the stock of Biogen is held by insiders.

Percentage Held by Institutions

87.93% of the stock of Biogen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BIIB Stock Analysis - Frequently Asked Questions

How have BIIB shares performed this year?

Biogen's stock was trading at $152.92 at the beginning of 2025. Since then, BIIB stock has decreased by 13.3% and is now trading at $132.6250.

How were Biogen's earnings last quarter?

Biogen Inc. (NASDAQ:BIIB) released its quarterly earnings results on Thursday, May, 1st. The biotechnology company reported $3.02 earnings per share for the quarter, missing analysts' consensus estimates of $3.26 by $0.24. Biogen's revenue was up 6.2% compared to the same quarter last year.
Read the conference call transcript.

Does Biogen have any subsidiaries?

Biogen subsidiaries include Nightstar Therapeutics plc, Convergence Pharmaceuticals, TYSABRI, Stromedix Inc., Panima Pharmaceuticals AG, Syntonix Pharmaceuticals Inc., Fumapharm, and more.

How do I buy shares of Biogen?

Shares of BIIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Biogen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Biogen investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA), Broadcom (AVGO) and Intel (INTC).

Company Calendar

• Last Earnings: 5/01/2025
• Today: 7/03/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BIIB
• CIK: 875045
• Web: www.biogen.com
• Phone: (617) 679-2000
• Fax: 617-679-2617
• Employees: 7,605
• Year Founded: 1978

Price Target and Rating

• Average Stock Price Target: $188.48
• High Stock Price Target: $292.00
• Low Stock Price Target: $115.00
• Potential Upside/Downside: +42.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.38
• Research Coverage: 32 Analysts

Profitability

• EPS (Trailing Twelve Months): $10.13
• Trailing P/E Ratio: 13.09
• Forward P/E Ratio: 8.38
• P/E Growth: 1.06
• Net Income: $1.63 billion
• Net Margins: 15.07%
• Pretax Margin: 17.85%
• Return on Equity: 14.03%
• Return on Assets: 8.32%

Debt

• Debt-to-Equity Ratio: 0.27
• Current Ratio: 1.44
• Quick Ratio: 1.01

Sales & Book Value

• Annual Sales: $9.68 billion
• Price / Sales: 2.01
• Cash Flow: $23.03 per share
• Price / Cash Flow: 5.76
• Book Value: $114.71 per share
• Price / Book: 1.16

Miscellaneous

• Outstanding Shares: 146,530,000
• Free Float: 146,264,000
• Market Cap: $19.43 billion
• Optionable: Optionable
• Beta: 0.14